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1. Introduction  
Rectal carcinoma is currently the fifth most common cancer in the United Kingdom, 
accounting for approximately 5800 deaths in the UK and 700,000 deaths worldwide 
annually (UK Cancer Research). The UK Co-ordinating Committee on cancer research 
defines rectal cancer as any tumour within 15cm of the anal verge on rigid sigmoidoscopy. 
The implementation of bowel screening programme has led to the identification of 
increasing numbers of early rectal cancer. An increasing elderly population associated with 
multiple co-morbidities has highlighted the importance of early diagnosis and local 
treatment options. It remains the leading cause of deaths in the over 75 year’s age group.  
Early rectal cancer is defined as invasive adenocarcinoma spreading into the submucosa 
or muscularis propria; T1 or T2 tumours in the tumour node metastasis (TNM) 
classification (Sobin & Wittekind, 2002) or Dukes’ A in the Dukes’ staging. These tumours 
have a smaller chance to metastasize to local lymph nodes compared to those invading 
deeper than the muscularis due to the scarce lymphatic system within colorectal mucosa 
(Day et al 2003).  
2. Epidemiology 
Colorectal cancer is the third most common cancer worldwide and the most common 
gastrointestinal malignancy in Western countries. From these, almost 30% arise in the 
rectum. The incidence of rectal cancer is higher in men (57.9%) when compared to women 
(42.1%), with women also showing an improved survival compared to men, 51.0% to 48.5% 
at 5 years. There has been a steady improvement in the mortality of rectal cancer but 5 year 
survival in Europe still falls short of American rates. Data collected from the 9 areas in USA 
over a 4 year period showed 5 year survival rates of 59-66% (Jeffreys et al., 2006; Sant et al., 
2003). 
3. Screening 
A population-based national screening programme was initiated in 2006 based on results of 
a pilot study of faecal occult blood testing (FOBT) in the UK. A number of countries have 
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recommended and now implemented FOBT into their health schemes. In the USA, the 
American College of Gastroenterology guidelines published in 1997 have stated 
asymptomatic individuals above the age of 50 years should have a FOBT +/- flexible 
sigmoidoscopy every 5 years, a double-contrast barium enema or colonoscopy every 10 
years.   
Colorectal cancer screening guidelines in high risk individuals are based on case-control 
studies comparing the incidence and the stage of the disease screened and control groups. 
About 10% of colorectal cancers run in family due to genetic predispositions (Lynch 
syndromes). All current evidence predicts that surveillance will improve disease specific 
survival in these patients. It has been established that screening the average risk population 
for colorectal cancer reduces cancer specific mortality by 15% with the FOBT and by 50-80% 
post flexible sigmoidoscopy (Rex, 2004; Sant et al., 2003). The international agreement and 
introduction of the FOBT will improve the prognosis of rectal cancer by improved early 
diagnosis. Further indirect benefits will also be seen due to increase endoscopic services and 
quality of endoscopic examinations.  
However the colorectal cancer screening programme with FOBT has limitations due to its 
inability to detect adenomas. The future will see a change from guaiac testing to the use of 
computed tomography scanning, flexible sigmoidoscopy and faecal DNA testing for 
selecting patients that need further colonoscopy and polypectomy (Rex, 2000).  
4. Investigations 
Before a management strategy is determined, preoperative imaging is essential in order to 
determine the stage of the tumour and, therefore, prognostic factors in a patient.  
Endorectal ultrasound (ERUS) is a diagnostic technique that allows the stage of both tumour 
invasion and lymph node metastatic involvement to be determined. Not only it is safe,it also 
plays a significant role in deciding the most adequate surgical strategy in patients with 
rectal carcinoma (Bhutani, 2009; Siddiqui et al., 2006). This diagnostic procedure has been 
used successfully in clinical practice since 1985 as a tool to stage rectal cancer and is most 
widely used in the United Kingdom.   
In order to perform ERUS, the rectum must be empty to ensure that there is no distortion of 
images due to the presence of faecal matter. Laxative enemas are sufficient for rectal lesions 
and a preparation is required for colonic lesions. Pre-examination sigmoidoscopy is 
performed to ensure the lumen is free of debris. ERUS is a well-tolerated procedure and 
usually does not require sedation.  
Carcinomas are hypoechoic, and the stage is determined by the scale to which they affect the 
rectal wall layers (Karantanas et al., 2007). The prefix “u” is used to represent stage and it 
corresponds to the TNM classification (Smith & Brown, 2008).  
 uT1 – tumour does not penetrate the muscularis propria.  
 uT2 – tumour penetrates the muscularis propria but not beyond it.  
 uT3 – tumour proceeds beyond the muscularis propria, infiltrating the perirectal fat to a 
variable degree.  
 uT4 – tumour infiltrates surrounding organ (Giovannini & Ardizzone, 2009).  
There have been meta-analyses carried out to determine the value of ERUS. It has been 
found to be very accurate for the staging of superficial rectal tumours, with accuracy in 
evaluating tumour ingrowths into rectal wall layers ranging from 69% to 97% (Gualdi et al., 
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2000). Furthermore, the sensitivity and specificity of ERUS to diagnose stage T1 cancer were 
87.8% and 98.3%, respectively; for stage T2 the sensitivity and specificity were 80.5% and 
95.6% respectively; for stage T3 the sensitivity and specificity were 96.4% and 90.6% 
respectively; for stage T4 the sensitivity and specificity were 95.4% and 98.3% respectively 
(Puli et al., 2009). ERUS is also good for differentiating early and advanced rectal lesions 
with a sensitivity of 96%, a specificity of 85% and an accuracy of 94% (Zorcolo et al., 2009). 
Also, there are data to suggest that ERUS is 62% to 92% accurate for T-staging and 64% to 
88% accurate for N-staging (Geibel & Longo, 2006).  
High-resolution three-dimensional ERUS is useful for assessing the depth of submucosal 
invasion in early rectal cancer and for selecting therapeutic options. Santoro et al. (2009) 
evaluated the accuracy of this modality in distinguishing slight from massive submucosal 
invasion of early rectal tumours in a prospective study. The depth of invasion was correctly 
determined in 87.2% of both pT1-slight and pT1-massive lesions. It also had an accuracy of 
95.2% in selecting appropriate management. A meta-analysis by Puli et al. (2010) also 
showed that ERUS had a sensitivity of 97.3% (95% CI: 93.7–99.1) and specificity of 96.3% 
(95% CI: 95.3–97.2) in diagnosing T0. Such excellent sensitivity can help physicians offer 
endoscopic treatment to patients with T0 stage rectal cancers. 
Through various research and clinical practice, ERUS has been found to be a safe and 
accurate method for staging rectal carcinoma, although it is operator-dependent. For this 
reason, adequate training and skill-development is essential.  
Other imaging modalities used for preoperative staging of rectal carcinoma include 
computed tomography (CT) scan, magnetic resonance imaging (MRI) and positron emission 
tomography (PET) scan (Geibel & Longo, 2006).  
An abdominopelvic CT scan is performed on the majority of patients with clinically 
localised rectal cancer in order to identify any intra-abdominal metastasis prior to curative 
or radical resection. However, its role in preoperative staging is much more limited with 
accuracy of T-staging being 53% to 94% and for N-staging 54% to 70%, which are 
substantially lower than ERUS (Schaffzin & Wond, 2004).  
MRI is also less accurate than ERUS for staging rectal cancer, with an accuracy of 52% in 
T-stage and 68% in N-stage (Chen et al., 2000). Most of the inaccuracy is due to 
overstaging caused by inability of MRI to differentiate treatment-induced fibrosis from 
viable tumours.  
Genetic and molecular research has also been performed by Zlobec, et al (2008), which 
aimed to determine an immunohistochemical protein profile to complement preoperative 
staging and identify rectal carcinoma patients at a high risk of an adverse outcome. Eight 
protein markers were selected for use in the investigation, based on their correspondence 
to various cellular processes and their prognostic value. These protein markers were 
APAF-1, EphB2, MSTI, Ki67, p53, RHAMM, RKIP and CD8+ tumour infiltrating 
lymphocytes (TL). 482 patients were retrospectively collected from three different centres 
in Switzerland. The inclusion criteria comprised of those patients with primary colorectal 
cancer who received treatment between 1987 and 1996. Patients were excluded from the 
study if their tumours were located in the colon or if the rectal carcinoma had been treated 
preoperatively. Clinicopathological features recorded for each participant included 
gender, pT and pN stage, tumour grade, vascular invasion, invasive margin, mismatch 
repair, recurrence, metastasis, postoperative therapy and 5-year survival. Follow-up 
reached 150 months. 
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Initial univariate survival analysis (Cox proportional hazards regression) for each protein 
marker showed that four markers were linked to survival time, including negative 
expression of Ki67, positivity for RHAMM, absence of RKIP and loss of CD8+ TILs. Further 
multivariable analysis found that only RHAMM (p<0.001; HR= 1.94 (1.44-2.61)) and loss of 
CD8+ TILs (p=0.006; HR= 0.63 (0.45-0.88)) were independent prognostic factors. 
Therefore, this study proposes that the immunohistochemical protein profile of RHAMM 
and CD8+ TILs can identify patients with adverse prognosis independent of the extent of the 
disease and. Collectively, they could aid in selecting early stage rectal cancer patients who 
are predominantly more likely to have poorer prognosis and thus will benefit the most from 
preoperative treatment. 
5. Management 
Radical surgery with total mesorectal excision (anterior resection and abdominoperineal 
excision) remains the ‘gold standard’ treatment for rectal cancer. Through this operation, 
both the primary tumour and the draining lymph nodes are removed which, in turn, leads 
to a reduction in recurrence. Although it gives the best chance of cure but have a significant 
risk of death (30-day mortality rate < 7%), morbidity (35%) and poor functional outcome 
(Association of Coloproctology of Great Britain and Ireland, 2007). One retrospective study 
evaluated 168 patients with T1-stage rectal cancer and found radical resection to have a local 
recurrence, distant recurrence and estimated 5-year overall recurrence of 3%, 3% and 6%, 
respectively (Bentrem et al., 2005). 
On the other hand, local treatment in the management of early rectal cancer aims to 
minimize morbidity and mortality but at the same time to offer cure. The importance of 
early diagnosis and local treatment options has been highlighted by the increasing numbers 
of early rectal cancer detected through the introduction of bowel screening programme, an 
increasing elderly population associated with multiple co-morbidities and the significant 
number of patients who are ‘stoma phobic’ and refuse conventional major surgery. The 
decision to offer local treatment for early rectal cancer must involve all members of the 
multidisciplinary team. 
Staging of the early rectal cancer is critical. Clinical staging of rectal cancer is based on TNM 
classification (Table 1). Histological assessment plays the most important factor in 
predicting the risk of lymphatic spread.  
When selecting patient for local treatment, the aim is to choose those with tumours confined to 
rectal wall with a low probability of lymph node metastases. Patients can be assessed by 
digital rectal examination supplemented by endoscopy and radiology [endorectal ultrasound 
or endorectal magnetic resonance imaging (MRI)]. Selection criteria and exclusion criteria for 
local treatment are summarized in table 3 and 4 (Hershman et al., 2003). 
Various local treatment options available will be discussed in the following paragraphs. 
However, combinations of local treatment options i.e. combined modality approach have 
been used successfully in treating early rectal cancer. 
5.1 Local surgical options  
5.1.1 Endoscopic Mucosal Resection (EMR) 
EMR is usually reserved for benign pedunculated or flat polyps. In the treatment of rectal 
cancer, it is suitable for very early malignant T1 tumours (sm1 or selected sm2) (Table 2) 
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(Kikuchi et al., 1995). It is performed under sedation without the requirement of general 
anaesthesia. Hence, it is a major advantage for very unfit patients. 
 
T – Primary tumour 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour invades submucosa (sm)  
T2 Tumour invades muscularis propria (MP) 
T3 Tumour invades through MP into subserosa or into non-peritonealised  
 pericolic or perirectal tissues 
pT3a Minimal invasion <1mm beyond MP 
pT3b Slight invasion 1-5mm beyond MP 
pT3c Moderate invasion >5 -15mm beyond MP 
pT3d Extensive invasion >15mm beyond MP 
T4 Tumour directly invades other organs or structures (T4a) 
 Tumour perforates the visceral peritoneum (T4b) 
 
N – Regional lymph nodes 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1 to 3 pericolic or perirectal lymph nodes 
N2 Metastasis in 4 or more pericolic or perirectal lymph nodes 
M – Distant metastasis 
Mx Presence of distance metastasis cannot be assessed 
M0 No distant metastases 
M1 Distant metastases 
Table 1. TNM Staging. 
 
Classification of submucosal invasion by early colorectal cancer 
 
Sm1 
a < ¼ of the width of the tumour invading the submucosa 
b ¼ or ½ the width of the tumour invading the submucosa 
c > ½ the width of the tumour invading the submucosa 
Sm2 Intermediate between Sm1 and Sm3 
Sm3 Carcinoma invasion near to the muscularis propria 
Table 2. Classification of submucosal invasion by early colorectal cancer according to 
Kikuchi et al. (1995). 
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Selection criteria for suitability of local treatment 
1. Mobile non-ulcerative exophytic tumours <10cm from anal verge (clinical assessment:
digital rectal examination) 
2. Tumour <3cm or occupying less than 1/3 of the circumference (endoscopic 
assessment) 
3. cT1/Tx/cN0/cM0 (radiological assessment: endorectal ultrasound/ MRI 
4. Well to moderately well differentiated tumours (histological assessment) 
5. No lymphovascular or venous invasion (histological assessment) 
6. Patient must agree on long-term follow up 
Table 3. Selection criteria for local treatment based on clinical practice of Dr. S Myint and 
Mr. M J Hershman. 
 
Exclusion criteria for local treatment 
1. Poorly differentiated tumour. 
2. T3/T4 tumour 
3. Clinically tethered or fixed tumour of any radiological T stage 
4. Deeply infiltrative ulcerative tumour 
Table 4. Exclusion criteria for local treatment based on clinical practice of Dr. S Myint and 
Mr. M J Hershman. 
During EMR, the polyp is assessed endoscopically, its base is then infiltrated by normal 
saline or gel to raise it away from the underlying muscle before it is resected using a 
diathermy or a hot loop. The specimen is then pinned and oriented for histological 
submission. EMR may not be appropriate if the polyp’s base cannot be raised suggesting the 
tumour is probably more advanced.  
The selection criteria for EMR in early rectal cancer are controversial, but generally include 
(Onozato et al., 2007): 
 Well or moderately differentiated adenocarcinoma 
 The mucosal or minute submucosal type 
 No lymphatic or vascular invasion 
No large studies have compared the effectiveness of EMR with transanal excision. A small 
retrospective study suggested that EMR was a safe and effective method for the treatment of 
early rectal cancer and its outcomes were comparable to those of transanal excision 
procedures (Lee et al., 2009) (complete resection was 93.8% for EMR vs. 87.5% for transanal 
excision; mean length of hospital-stay was 2.7 for EMR vs. 8.9 for transanal excision; no 
recurrence disease in either group at median follow up of 15 months). There were no 
significant differences between the two study groups with regard to rectal cancer size, 
location from the anal verge and histological differentiation. 
A prospective study in Sheffield, UK suggested extended EMR for rectal neoplastic lesions 
can achieve superior results to those of per-anal excision and trans-anal microsurgery with 
regard to complications and recurrence rates (Hurlstone et al., 2005). The 30-day 
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readmission and death rate was 0%, bleeding 8%; no procedural related complications or 
perforation with overall ‘cure’ rate of 98% at a median follow-up of 16 months.  
5.1.2 Transanal Resection (TAR) / Transanal Endoscopic Microsurgery (TEM) 
Locoregional treatment for early rectal cancer is gaining popularity compared with standard 
treatment of radical surgery (anterior or abdominoperineal resection). Local procedures for 
strictly selected patients should lead to similar oncological results and even better outcomes 
in terms of morbidity, mortality and quality of life (Moore & Guillem, 2002). 
Conventional TAR allows the excision of tumours in the lower rectum using anal retractors. 
Preoperative staging is very important in determining TAR as an option for treating early 
rectal cancer. It is generally agreed that the criteria for TAR are (Stamos & Murrell, 2007): 
 Mobile, non ulcerated T1 or T2 tumour 
 Nodes negative on ultrasound 
 < 8cm from anal verge 
 Occupying < 1/3 of the circumference 
 Low grade tumours (well or moderately differentiated) 
 Favourable histology on biopsy without lymphovascular invasion 
It should be performed as a full thickness resection down to perirectal fat, along with a 1cm 
radial margin. The defect is usually closed but it can be left open. The specimen should then 
be pinned and oriented for histology submission. 
TAR is associated with relatively low morbidity and mortality, decreased hospital stay and 
has minimal effect on sphincter function. However, this technique is associated with 
relatively high rates of local recurrence when compared with standard excision (11.0%vs. 
1.6% ; 13.2% vs. 2.7%) especially in patients with a high-grade tumour, or perineural or 
lymphovascular invasion (Nash et al., 2009; Peng et al., 2011).  
If there are unfavourable pathological features like positive resection margins, 
lymphovascular invasion, lymph node metastasis, perineural invasions and recurrent lesion 
at follow-up; salvage surgery must be considered.  
In summary, TAR has low morbidity and mortality, rapid recovery times and allows 
preservation of sphincter function but is associated with higher rate of recurrence especially 
high grade tumour and those with perineural or lymphovascular invasion. Therefore, it is 
essential to have strict selection criteria when considering this technique and patients should 
be informed of the risk of local recurrence and the need of frequent follow up. 
TEM was first described by Buess in 1984 (Buess et al., 1983, 1984). A resectoscope is used to 
give stereoscopic view of the rectum and distal sigmoid colon. The rectum is distended with 
insufflated carbon dioxide to allow the passage of dissecting instruments. It has an 
exceptionally clear magnified view of the mucosa allows precise removal of mucosal lesions 
and avoiding the need for radical surgery. TEM is theoretically suitable for tumours lying 
up to 25cm from the anal verge, unlike TAR which only offers overview of the lower 
rectum. However, the procedure is usually used for tumours below the peritoneal reflection 
due to risk of intraperitoneal perforation, technical difficulty and unavailability of 
preoperative staging with endorectal ultrasonography for proximally sited tumours 
(Sharma et al., 2003). 
TEM represents an effective curative treatment for pT1 sm1 rectal malignancies. A 
prospective study included 107 patients who had adenocarcinoma: 48 pT1, 43 pT2, and 16 
pT3; the 5-year disease-free survival rate was 85.9%, 78.4%, and 49.4% respectively 
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(p = 0.006). Recurrence rate was 0% (0/26) in pT1sm1 cancers and 22.7% (5/22) in sm2-3 
(p < 0.05) (Morino et al., 2011). A submucosal infiltration represented a significant risk factor 
for recurrences: 0% sm1, 16.7% sm2, and 30% sm3.  
Another prospective study (Ramirez et al., 2011) also supports transanal endoscopic 
microsurgery as an adequate treatment for T1 low-risk tumour and no additional measures 
are required. The five-year overall survival was 94% and cancer-specific survival was 96%. 
In addition, the quality of resection is better with TEMS than with TAR as shown in a 
retrospective study with 42 TEM and 129 TAR patients (Christoforidis et al., 2009). 
The reasons for the superiority of TEM over TAR include: 
 The use of an optical system with 3D-view  
 6-fold magnification  
 The creation of a stable pneumorectum 
 Specially designed instruments allow full-thickness excision under direct observation in 
the lower, middle and even upper parts of rectum 
 Full thickness excision allows proper histological examinations 
There are no large head to head studies comparing TEM with conventional radical 
surgery. There is 1 small prospective randomized trial and 2 retrospective cohort studies 
comparing TEM with radical surgery (Heintz et al., 1998; Lee et l., 2003; Winde et al., 
1996) (Table 5). According to study by Winde et al, there was no significant difference in 
the local recurrence rate or the survival rate for patients treated with TEM or anterior 
resection. However, the power of the study was inadequate. Lee et al also reported similar 
outcomes for patients with T1 and T2 rectal cancers underwent TEM or radical surgery. 
Study by Heintz et al is difficult to interpret due to inclusion of patients who had 
inadequate local surgery. 
TEM is a safe technique with low morbidity and recurrence rates (Koebrugge et al., 2009). 
Experience over times has led to a reduction in operation time, length of patients' hospital 
stay and complication rate. TEM remains the treatment of choice for stage T1 low risk rectal 
carcinomas. Patient with pT1 sm2-3 and T2 low risk lesions should be considered high-risk 
cases if treated only by TEM (Morino et al., 2011; Ramirez et al., 2011). 
5.2 Contact radiotherapy 
Rectal adenocarcinoma is radio-resistant. Doses above 80Gy are necessary and need to be 
delivered by endocavitary irradiation (contact x-ray therapy, brachytherapy) with high 
doses targeting the tumour but low doses to normal tissue.  
Contact radiotherapy or known as Papillon’s technique was developed in the 1950s and is 
performed with a 50kV hand held tube which is capable of delivering a dose of 20 Gy per 
minute. The percentage dose is 100% at 0mm, about 50% at 5mm depth and 20% at 10mm. 
The scatter from the tube is negligible. 
For a T1N0 tumour, treatment is divided into 4 sessions: 
 35 Gy on day 1 
 30 Gy on day 7 
 20 – 25 Gy on day 21 
 10 – 20 Gy on day 35 
The total dose may range from 80 – 110 Gy in four to five fractions depending on the initial 
size of the tumour and the shrinkage of the tumour which is measured on day 21. If a 
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complete response is achieved at this stage, the chance of control with radiotherapy alone is 
very high. However, if there is still a visible lesion, patient should be referred for surgery or 
the dose increased to 100 – 120 Gy and combined with external-beam radiotherapy and a 
brachytherapy boost if inoperable.  
 
Transanal Endoscopic Microsurgery Versus Radical Surgery for T1 and T2 Rectal Cancer 
Study T Stage
TEM / 
Radical 
surgery (RS) 
Number of 
patients 
Local 
recurrence rate 
(%) 
Overall 
survival 
rate (%) 
Follow-up 
(Months) 
Winde et al 
(1996) 
1 
TEM 24 4.2 96 
46 
RS 26 0 96 
Lee et al (2003) 
1 
TEM 52 4.1 100 
31-35 
RS 17 0 93 
2 
TEM 17 19.5 (p<0.05) 95 
RS 83 9.4 96 
Heintz et al 
(1998) 
1  
(Low 
risk) 
TEM 46 4.4 79 
42-52 
RS 34 2.9 81 
1  
(High 
risk) 
TEM 12 33 62 
RS 11 18.2 69 
Table 5. Summary of results for TEM vs. Radical surgery studies. 
Gerald et al (2002) reported contact radiotherapy can achieve local control in 85 – 90% of 
patients with T1N0 tumours, good tolerability in most with preservation of good anorectal 
function and no severe late toxic effects. 
Sun Myint et al (2007) at Clatterbridge, UK reported their experience of treating patients 
with early rectal cancer using multimodality approach including contact radiotherapy. 
Clatterbridge uses the Therapax 50kV machine with a 0.5mm Al filter as opposed to the 
Philips machine. At Clatterbridge, patients who do not respond well to initial contact 
radiotherapy are offered external-beam radiotherapy alone, delivering 45Gy in 20 
fractions over 4 weeks or chemoradiotherapy with 45Gy in 25 fractions over 5 weeks with 
5-fluorouracil infusion 750-1000mg/m2 in weeks 1 and 5. 5-fluorouracil has been changed 
to oral capecitabine 825mg/m2 on the days of radiotherapy. From their experience, 124 
out of 220 patients had Papillon’s contact radiotherapy as part of the multimodality 
treatment. There were 24/220 (11%) with residual disease after initial radiotherapy. 71% 
of patients were still alive at a median follow-up of 4.6 years. The cancer specific survival 
was 93%.  
Therefore, contact therapy is an efficient treatment for T1N0 rectal adenocarcinoma. It has 
the advantage of not needing general anaesthesia, can be performed on an outpatient basis, 
can be used to treat frail elderly patients and no risk of fistula. 
For T2-3N0-1 tumours, the standard treatment is radical surgery. However, this may not be 
suitable if the patient has high co-morbidity or patient refuses to have permanent colostomy. 
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In these situations, a combination of contact radiotherapy and external-beam radiotherapy, 
brachytherapy or both may be considered. The combination treatment is essential as contact 
therapy alone is insufficient to penetrate the deeper layers of the rectal wall and no 
irradiation reaches the perirectal lymph nodes which are at high risk of involvement. 
5.3 Local excision and adjuvant therapy 
Postoperative radiation and chemotherapy have been used as an alternative to radical 
surgery to reduce the risk of local recurrence for patients. There are studies to suggest lower 
trends of local recurrence rates and higher disease free survival (DFS) rates with adjuvant 
therapy compared with local excision alone, especially in T2 tumours or in higher grade 
tumours. 
Retrospective study by Chakravarti et al (1999) compared patients with T1/T2 rectal cancer 
treated by local excision alone with those treated by local excision plus adjuvant radiation 
therapy. There was no difference in the 5-year local recurrence and DFS between the 2 
groups even though there were significantly higher proportions of T2 tumours and T1 
tumours with unfavourable histological features in the radiation therapy group. However, 
subgroup analysis of high-risk patients showed substantially better local control rate with 
the addition of postoperative radiation (85% vs. 37% local excision alone). 
A prospective multi-institutional trial by The Cancer and Leukaemia Group B comparing 
the outcomes of 59 patients with T1 lesions treated with local excision alone with those 51 
patients with T2 lesions treated with local excision and postoperative chemoradiation 
(Greenberg et al., 2008). The recurrence rates were 7% for the T1 and 14% for T2 at a median 
follow-up of 7 years. 
The Radiation Oncology Therapy Group study evaluating adjuvant chemoradiation therapy 
after local excision reported a 16% (8 out of 65) locoregional recurrence rate (Russell et al., 
2000). The risk of recurrence correlated with T stage (T1 4%, T2 16%, T3 23%). 
Despite the lack of randomized control trials, there are data to support benefit of adjuvant 
chemoradiation or radiation therapy after local excision for patients with T2 or in higher-
grades tumours. More studies are still required before this can be adopted to routine clinical 
practice. 
5.4 Local excision after neoadjuvant therapy 
Local excision after neoadjuvant therapy may be considered for patients who refuse radical 
surgery or candidates who are at high risk of surgery due to significant medical co-
morbidities. 
Lezoche et al (2005) reported 2.8% (1 out of 106) recurrence rate in T2 rectal cancer patients 
treated with preoperative chemoradiotherapy followed by TEM at a median follow up of 38 
months. This group has further conducted a randomised trial of preoperative 
chemoradiotherapy followed by TEM vs. radical surgery alone. This trial showed equivalent 
local control and survival at a median follow-up of 4-years however this study did not have 
adequate study power. 
Although robust evidence is still lacking to support the routine use of neoadjuvant therapy 
with local excision, the tumoricidal effect of neoadjuvant chemoradiation is well 
documented in patients with advanced rectal cancer treated with radical surgery. Hence, it 
is reasonable to project the benefits of neoadjuvant therapy in treating patients with early 
rectal cancer by local excision especially in T2 tumours. 
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5.5 Salvage surgery after local excision  
Salvage surgery can be offered to patients who have failed local treatment of early rectal 
cancer. There are two types available: 
 Immediate salvage (rescue surgery)  
 This is performed within 6 months of the completion of local treatment. 
 This includes patients with inadequate resection margins of local surgery, 
unfavourable pathology and failure to eradicate tumour with local treatment. 
 Delayed salvage  
 This is carried out for local recurrence after an apparent cure of cancer that has 
been sustained for a minimum of 3 months. 
Hershman and Sun Myint (2007) reported that salvage surgery was an effective 
management after fail local treatment with an overall salvage rate of 68% (30/44) and a 
salvage cure rate of 87% (26/30). Mellgren et al (2000) reported a 5-year disease-free survival 
rate of 50% in 24 out of 25 patients with local recurrence treated with radical salvage 
surgery. 
Therefore, intensive follow-up after initial local treatment in the first 3 years is important in 
order to identify patients who are suitable for salvage surgery and to enable prompt 
treatment. 
Treatment Algorithm for Patients with Early Rectal Cancer are summarised in Table 6. 
6. Complications 
6.1 EMR 
EMR is usually tolerated without many side effects. However, bleeding and recurrence has 
been reported especially for those with submucosal cancer. A retrospective study by Kim et 
al (2011) reported that 7 out of the 65 patients with submucosal cancer who underwent EMR 
showed adverse outcomes within 3 years: recurrence or residual of primary cancer or lymph 
node metastasis. 
Metz et al (2011) reported 7% (21 out of 288 patients) experienced clinically significant 
delayed bleeding after undergoing EMR for laterally spreading tumours of 20mm or greater. 
10 underwent colonoscopy, 1 required angiography and 1 required surgery after perforation 
following hemostatic clip placement. These were data analysed from two large prospective 
intention-to-treat studies of EMR. Their data have shown that proximal lesion location is a 
highly significant risk for clinically significant delayed bleeding following colonic EMR. 
Recent aspirin use also increases bleeding risk. Surprisingly, larger lesion size (P = 0.2), 
multiple excisions rather than en bloc resection (P = 0.1), polyp morphology (P = 0.2), and 
previous attempts ( P = 0.5) are not associated with increased risk of bleeding. 
6.2 TAR 
TAR has been reported to be associated with local recurrence in the treatment for early 
rectal cancer. Taylor et al (1998) report a 30% recurrence rate for T1 and T2 tumours treated 
by local excision alone, Grarcia-Anguilar et al (2000) reported 18% recurrence with T1 
tumours and 37% with T2 tumours at 54 months of follow up, Madbouley et al (2005) 
reported overall recurrence rate of a 28.8% in T1 rectal cancer and Huh et al (2009) reported 
similar recurrence rate of 28.5% in early rectal tumours with favourable pathologic features 
at median follow-up of 66 months. 
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Local excision does not remove lymph nodes in the mesorectum, therefore, when 
considering patients for local excision, strict selection criteria are essential to give more 
favourable outcomes. Risk of lymph nodes involvement is 0-12% for T1 cancer and 12-28% 
for T2 cancers (Sengupta & Tjandra, 2001). Features associated with a significantly increased 
risk of lymph node metastases include poor differentiation, lymphovascular invasion and 
size greater than 3cm (Chambers et al., 2004; Nascimbeni et al., 2002). 
6.3 TEM 
Although TEM represents an effective curative treatment for pT1 sm1 rectal cancer, it can be 
associated with recurrence in pT1 sm2-3 patients. Study by Morino et al (2011) showed that 
recurrence rate was 0% (0/26) in pT1sm1 cancers and 22.7% (5/22) in sm2-3 (p < 0.05). In 
addition, other risk factors associated with recurrence include pT2 leisons and lesions larger 
than 3cm. Acording to a retrospective study by Yu et al (2011) involving 60 patients who 
underwent TEM, there was a significant difference in local recurrence rate between pT1 and 
pT2(2.6% vs. 40.0%, P<0.05). The recurrence rate was higher in lesions larger than 3 cm 
compared to those lesions smaller than 3cm(19.0%, 4/21 vs. 2.6%, 1/39, P<0.05) (Yu et al., 
2011). 
6.4 Contact radiotherapy 
The main side effect of endocavitary irradiation (contact radiotherapy with or without 
iridium brachytherapy) combined with external-beam radiotherapy is rectal bleeding, which 
may require argon laser treatment. Other side effects include bowel urgency and frequency 
in the morning which do not generally affect normal life (Gerald et al., 2002). Late toxic 
effects include rectal fibrosis or stenosis and rectal ulcers with persistent bleeding leading to 
chronic anaemia have been reported (Birnbaum et al., 1994; Cho et al., 1995; Letschert, 1995). 
7. Conclusion 
Local treatment of early rectal cancer remains an attractive alternative to radical surgery in 
the current climate of increasing ageing population and the numbers of early rectal cancer 
detected through colorectal screening programme. This option is suitable for elderly 
patients, those patients with significant medical co-morbidities who are at increased 
operative risk and those who are stoma averse. Unlike radical surgery, it is associated with 
relatively low morbidity and mortality, decreased hospital stay and has minimal effect on 
sphincter functions. Although this treatment option is still debated, local excision alone 
should be used for selected patients with T1 tumours or low risk T2 tumours and patients 
should be informed of the risk of local recurrence and the need of frequent follow up. 
Contact radiotherapy is an efficient treatment for T1N0 rectal adenocarcinoma. It has the 
advantage of not needing general anaesthesia, can be performed on an outpatient basis, can 
be used to treat frail elderly patients and no risk of fistula. A combination of contact 
radiotherapy and external-beam radiotherapy, brachytherapy or both may be considered for 
patients with T2-3N0-1 tumours. Salvage surgery can be offered to patients with 
recurrences. Combination of local excision with adjuvant and neoadjuvant therapies may 
play a role in the treatment of early rectal cancer but more trials are needed. Patients and 
relatives should be informed fully regarding treatment options available and the side effects 
associated with each treatment. Careful selection of patient and preoperative staging are 
paramount for the successful outcome of multimodality approach and all multidisciplinary 
team members must be involved in order to deliver high quality of care to patients. 
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Table 6. Treatment Algorithm for Patients with Early Rectal Cancer. 
Clinical 
Stage  
Primary 
Treatment
Pathology After 
Local Excision
Additional 
Treatment 
<3cm 
T1N0M0/ 
T2N0M0 
Local Excision 
(TEM/TAR)
T1 Negative CRM
T2 Negative CRM
T1 Positive / 
Uncertain CRM
T2 Positive CRM 
Low risk -close 
follow up 
 
High risk (sm3, 
vascular / lymphatic 
invasion, G3, 
positive CRM) – 
additional treatment 
as T2 tumour  
Postoperative 
radiotherapy or 
chemoradiotherapy 
Possibility of 
conventional radical 
surgery 
Immediate 
conventional radical 
surgery 
If unfit or refuse 
surgery, then 
postoperative 
radiotherapy or 
chemoradiotherapy 
Endocavity 
radiotherapy / 
Papillon’s 
technique: 
for unfit patients 
at presentation 
(ASAIII or above), 
patients refuse 
surgery 
>3cm 
T1N0M0/ 
T2N0M0 
External beam 
radiotherapy / 
chemoradiotherap
y followed by 
local resection 
Negative CRM
Positive CRM Immediate 
conventional 
radical surgery 
Close Follow 
up
Intracavity boost 
(Papillon’s) for 
patients unfit for 
surgery 
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